Stuart Naylor, the Chief Scientific Officer, Ophthalmology of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 27,659 shares of ordinary shares on July 7, 2026, according to an SEC Form 4 filing.
Transaction summary
Key questions
-
What were the execution details regarding the price of the sold shares?
The transaction was carried out in multiple tranches with prices ranging from $13.36 to $15.33, resulting in a weighted average execution price of $14.80 per share. -
How does this sale fit into the insider’s broader investment strategy?
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, which allows insiders to diversify their portfolios through pre-scheduled transactions. -
What is the scale of the remaining equity position held by the insider?
Following this 4% reduction in direct holdings, Stuart Naylor retains 641,000 shares of MeiraGTx, which had a total market value of $9.39 million based on the July 7, 2026 close of $14.66. -
What has been the recent market context for MeiraGTx stock?
At the time of the transaction, MeiraGTx had realized a one-year return of 89%, with the stock priced at $13.89 as of the July 6, 2026 market close.
Company Overview
Company Snapshot
-
MeiraGTx is a clinical-stage gene therapy company developing therapeutic solutions for serious illnesses, including inherited ocular diseases, xerostomia following radiation treatment for head and neck cancers, and various degenerative and neurodegenerative disorders.
-
The company generates revenue through its clinical-stage gene therapy programs and development partnerships, with a business model focused on advancing proprietary gene therapy candidates through clinical development toward commercialization.
-
MeiraGTx targets patients suffering from serious genetic and degenerative conditions, with primary focus on ophthalmology, oncology supportive care, and neurodegenerative disease markets.
MeiraGTx Holdings plc operates as a clinical-stage biotechnology company with a market capitalization of $1.4 billion. The company has demonstrated significant momentum, with its stock appreciating 89% over the past year, reflecting investor confidence in its gene therapy pipeline. MeiraGTx’s competitive positioning centers on its proprietary gene therapy platform targeting high-unmet-need indications across multiple therapeutic areas, though the company remains in clinical development stages with negative net income reflecting typical early-stage biotech investment patterns.
